Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Sorrento Therapeutics, Inc. (SRNE)
USD0.00
+0.00 (+0.00%)
US OTC Healthcare Biotechnology
Address
4955 Directors Place 92121
San Diego, CA, US
San Diego, CA, US
CEO
Henry H. Ji
Website
sorrentotherapeutics.com
IPO
2007-01-19
CIK 850261 ISIN US83587F2020
Also trades on
London Stock Exchange · 0L85.L (USD)
Other OTC · SRNE (USD)
Other OTC · SRNEQ (USD)
Description
Sorrento Therapeutics, Inc. is a biopharmaceutical company, active in both clinical development and commercial operations, dedicated to creating treatments for a range of serious conditions including cancer, autoimmune disorders, inflammatory diseases, viral infections, and neurodegenerative ailments. The company's operations are divided into two distinct segments: Sorrento Therapeutics and Scilex. A core focus lies in cancer therapeutics, where Sorrento harnesses its proprietary G-MAB antibody library. This is complemented by advanced, targeted delivery systems such as chimeric antigen receptor T-cell therapy (CAR-T), dimeric antigen receptor T-cell therapy, antibody-drug conjugates, and innovative bispecific antibody approaches. Additionally, their Sofusa drug delivery technology offers a unique method for introducing biologics directly into the lymphatic system. Sorrento's clinical pipeline features several promising candidates. These include an anti-CD38 CAR-T therapy currently being developed for multiple myeloma, amyloidosis, and graft-versus-host disease. They are also advancing resiniferatoxin, a non-opioid-based TRPV1 agonist neurotoxin, for managing late-stage cancer pain and osteoarthritis knee pain. Furthermore, ZTlido, a lidocaine delivery system, addresses postherpetic neuralgia. Other significant developments comprise SEMDEXA, an injectable viscous gel in Phase III trials for sciatica, a specific form of low back pain; SP-103, an investigational non-aqueous lidocaine topical system targeting chronic low back pain; and SP-104, a novel low-dose delayed-release naltrexone hydrochloride formulation for fibromyalgia treatment. The company actively engages in strategic collaborations, including partnerships with SmartPharm Therapeutics Inc. to develop a gene-encoded antibody vaccine against COVID-19, and with Celularity, Inc. for a Phase I/II clinical study involving up to 94 COVID-19 patients. Sorrento also works with the Mount Sinai Health System on COVI-SHIELD, an antibody therapy designed to combat SARS-CoV-2 infection, and with the Mayo Clinic on a Phase Ib pilot study utilizing the Sofusa lymphatic drug delivery technology for Ipilimumab in melanoma patients. Established in 2006, Sorrento Therapeutics, Inc. is headquartered in San Diego, California.
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
USD0.00
+0.00 (+0.00%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
505.1K
Beta
0.15
Float Shares
539.11M
Free Float %
97.8%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +0.00% | -12.50% | -69.57% | -76.67% | -92.22% | -73.08% | -66.67% | +288.89% | -98.94% | -98.75% | -99.19% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Analyst Consensus (15 ratings, all time)
Buy
Price Targets & DCF
Current price
0.00
Ratings Trend (MoM)
100% Bullish
| Rating | 2024-11 | Change |
|---|---|---|
| Strong Buy | 1 | 0 |
| Buy | 1 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Quality scores
Altman Z-Score
-10.88
Distress
Piotroski F-Score
3 / 9
Average
MOAT Score
2 / 10
No MOAT
Operational MOAT
✗ Below peers
-
Revenue growth Biotechnology: +1.6%+18.8% ★ Q2'23: +31.1% (vs Q2'22)
-
EPS growth Biotechnology: +29.7%+6.2% Q2'23: +69.1% (vs Q2'22)
-
FCF margin FCF growth · Biotechnology: +16.2%-779.4% Q2'23: -371.4% (vs Q2'22)
-
EBIT margin Biotechnology: +0.0%-880.3% Q2'23: -700.1% (vs Q2'22)
-
ROIC Biotechnology: -16.1%-880.1% Q2'23: +592.7% (vs Q2'22)
-
Share dilution Biotechnology: -3.4%+42.3% Q2'23: +36.9% (vs Q2'22)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×-0.25× Q2'23: -0.52× (vs Q2'22)
Valuation Multiples
From
To
Price Forecast (3Y)
From
To
Theoretical Return — If Invested Today
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Consensus Estimates
| Metric |
Dec 2015 actual |
Dec 2016 actual |
Dec 2017 actual |
Dec 2018 actual |
Dec 2019 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 1 Rev. Ana. 1 EPS Ana. |
Dec 2027 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
4.59M
est: 4.39M (+4.7%)
|
8.15M
est: 6.11M (+33.4%)
|
151.86M
est: 144.18M (+5.3%)
|
21.19M
est: 17.77M (+19.2%)
|
31.43M
est: 25.00M (+25.7%)
|
39.99M
est: 1.04B (-96.2%)
|
52.90M
est: 52.90M (+0.0%)
|
62.84M
est: 42.24M (+48.8%)
|
24.66M
est.
|
185.75M
est.
|
382.72M
est.
|
591.41M
591.41M – 591.41M
+54.5% YoY
|
761.59M
761.59M – 761.59M
+28.8% YoY
|
| EBITDA |
-9.74M
est: -4.39M (-122.1%)
|
-60.34M
est: -6.11M (-887.2%)
|
27.38M
est: -144.18M (+119.0%)
|
-147.10M
est: -17.77M (-727.7%)
|
-308.40M
est: -25.00M (-1,133.6%)
|
-275.69M
est: -256.04M (-7.7%)
|
-435.99M
est: -325.45M (-34.0%)
|
-539.93M
est: -375.01M (-44.0%)
|
-461.08M
est.
|
-185.75M
est.
|
-382.72M
est.
|
-591.41M
-591.41M – -591.41M
-54.5% YoY
|
-761.59M
-761.59M – -761.59M
-28.8% YoY
|
| EBIT |
-8.07M
est: -4.39M (-84.0%)
|
-63.66M
est: -6.11M (-941.5%)
|
20.30M
est: -144.18M (+114.1%)
|
-156.15M
est: -17.77M (-778.6%)
|
-324.53M
est: -25.00M (-1,198.1%)
|
-290.42M
est: -250.80M (-15.8%)
|
-452.30M
est: -435.75M (-3.8%)
|
-553.17M
est: -485.23M (-14.0%)
|
-539.85M
est.
|
-185.75M
est.
|
-382.72M
est.
|
-591.41M
-591.41M – -591.41M
-54.5% YoY
|
-761.59M
-761.59M – -761.59M
-28.8% YoY
|
| Net Income |
-45.81M
est: -655.53M (+93.0%)
|
-60.92M
est: -591.23M (+89.7%)
|
9.06M
est: -96.44M (+109.4%)
|
-203.54M
est: -627.58M (+67.6%)
|
-359.10M
est: -566.08M (+36.6%)
|
-298.46M
est: -279.82M (-6.7%)
|
-429.01M
est: -351.75M (-22.0%)
|
-572.84M
est: -404.02M (-41.8%)
|
-493.22M
est.
|
-138.37M
est.
|
33.55M
est.
|
184.50M
184.50M – 184.50M
+450.0% YoY
|
280.94M
280.94M – 280.94M
+52.3% YoY
|
| SGA |
20.13M
est: 13.88M (+45.0%)
|
22.18M
est: 19.35M (+14.6%)
|
32.96M
est: 456.35M (-92.8%)
|
63.64M
est: 56.25M (+13.1%)
|
103.56M
est: 79.13M (+30.9%)
|
116.18M
est: 125.23M (-7.2%)
|
196.86M
est: 167.45M (+17.6%)
|
182.34M
est: 133.70M (+36.4%)
|
78.04M
est.
|
587.91M
est.
|
1.21B
est.
|
1.87B
1.87B – 1.87B
+54.5% YoY
|
2.41B
2.41B – 2.41B
+28.8% YoY
|
| EPS |
-1.24
est: -1.56 (+20.7%)
|
-1.21
est: -1.41 (+14.2%)
|
0.13
est: -0.23 (+156.5%)
|
-1.92
est: -1.50 (-28.3%)
|
-2.56
est: -1.35 (-89.6%)
|
-1.30
est: 1.83 (-170.9%)
|
-1.46
est: -1.45 (-0.7%)
|
-1.37
est: -1.05 (-30.5%)
|
-0.80
est.
|
-0.33
est.
|
0.08
est.
|
0.44
0.44 – 0.44
+450.0% YoY
|
0.67
0.67 – 0.67
+52.3% YoY
|
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
-231.33M
OE per share TTM
-0.48
Owner's Yield
-59,945.04%
Maintenance CapEx ratio
—
Maint CapEx / Avg PPE
128.0%
Ownership Overview
Ownership breakdown
Ownership breakdown not available.
At a glance
Institutional holders
—
Total invested
—
Insider transactions (90d)
0
Beneficial owners (>5%)
37
Beneficial owners (>5%)
| # | Reporting person | Amount owned | % of class | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Type | Citizenship | Filing date | SEC filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Sorrento Therapeutics, Inc. | 167.89M | 96.30% | 167.89M | — | 167.89M | — | HC, CO | — | 2022-11-17 | ↗ |
| 2 | STATE STREET CORPORATION | 39.66M | 10.20% | — | — | — | 39.66M | HC | BOSTON, MASSACHUSETTS | 2022-07-11 | ↗ |
| 3 | SSGA FUNDS MANAGEMENT, INC. | 32.62M | 8.39% | — | — | — | 32.62M | IA | BOSTON, MASSACHUSETTS | 2022-07-11 | ↗ |
| 4 | (1) BlackRock, Inc. | 21.78M | 6.90% | 21.09M | — | 21.78M | — | HC | Delaware | 2022-02-07 | ↗ |
| 5 | Sorrento Therapeutics, Inc. | 20.42M | 16.70% | 20.42M | — | 20.42M | — | CO | Delaware | 2021-07-23 | ↗ |
| 6 | The Vanguard Group - 23-1945930 | 15.69M | 5.12% | — | 532.3K | — | 791.1K | IA | Pennsylvania For | 2022-02-10 | ↗ |
| 7 | Israel A. Englander | 14.52M | 3.10% | — | 14.52M | — | 14.52M | IN | — | 2023-02-17 | ↗ |
| 8 | Millennium Group Management LLC | 14.52M | 3.10% | — | 14.52M | — | 14.52M | OO | — | 2023-02-17 | ↗ |
| 9 | Millennium Management LLC | 14.52M | 3.10% | — | 14.52M | — | 14.52M | OO | — | 2023-02-17 | ↗ |
| 10 | ICS Opportunities, Ltd. | 11.38M | 2.40% | — | 11.38M | — | 11.38M | CO | — | 2023-02-17 | ↗ |
| 11 | Sino Limited | 10.59M | 6.20% | 10.59M | — | 10.59M | — | CO | Virgin Islands | 2020-02-10 | ↗ |
| 12 | Oaktree Capital Group Holdings GP, LLC | 7.62M | 5.50% | 7.62M | — | 7.62M | — | PN | Delaware | 2019-09-25 | ↗ |
| 13 | Oaktree Capital Group, LLC | 7.62M | 5.50% | 7.62M | — | 7.62M | — | PN | Delaware | 2019-09-25 | ↗ |
| 14 | Oaktree Holdings, Inc. | 7.62M | 5.50% | 7.62M | — | 7.62M | — | PN | Delaware | 2019-09-25 | ↗ |
| 15 | Famous Sino Limited | 5.96M | 2.30% | 5.96M | — | 5.96M | — | CO | British Virgin Islands | 2021-02-01 | ↗ |
| 16 | Oaktree Capital II, L.P. | 5.11M | 3.68% | 5.11M | — | 5.11M | — | PN | Delaware | 2019-09-25 | ↗ |
| 17 | Oaktree Fund GP II, L.P. | 5.11M | 3.68% | 5.11M | — | 5.11M | — | PN | Delaware | 2019-09-25 | ↗ |
| 18 | Oaktree Fund GP IIA, LLC | 5.11M | 3.68% | 5.11M | — | 5.11M | — | PN | Delaware | 2019-09-25 | ↗ |
| 19 | Yu Fan | 4.91M | 2.90% | — | 4.91M | — | — | IN | Hong Kong | 2020-02-14 | ↗ |
| 20 | China In Shine Investment Limited | 4.76M | 1.80% | 4.76M | — | 4.76M | — | CO | British Virgin Islands | 2021-02-01 | ↗ |
| 21 | Ally Bridge Group Innovation Capital Partners III, L.P. | 4.45M | 2.70% | — | 4.45M | — | — | PN | Cayman Islands | 2020-02-14 | ↗ |
| 22 | Hongguo International Holdings Limited | 4.07M | 1.50% | 4.07M | — | 4.07M | — | CO | British Virgin Islands | 2021-02-01 | ↗ |
| 23 | Asia Pacific MedTech (BVI) Limited | 3.55M | 1.30% | 3.55M | — | 3.55M | — | CO | British Virgin Islands | 2021-02-01 | ↗ |
| 24 | Nana Gu | 3.55M | 1.30% | 3.55M | — | 3.55M | — | IN | British Virgin Islands | 2021-02-01 | ↗ |
| 25 | Magnum Opus2 International Holdings Limited | 3.34M | 1.30% | 3.34M | — | 3.34M | — | CO | British Virgin Islands | 2021-02-01 | ↗ |
| 26 | SC Investments E Holdings, LLC | 3.05M | 2.20% | 3.05M | — | 3.05M | — | PN | Delaware | 2019-09-25 | ↗ |
| 27 | ABG SRNE Limited | 3.04M | 1.80% | — | 3.04M | — | — | CO | British Virgin Islands | 2020-02-14 | ↗ |
| 28 | Oaktree Capital Management, L.P. | 2.52M | 1.81% | 2.52M | — | 2.52M | — | PN | Delaware | 2019-09-25 | ↗ |
| 29 | SC Investments NE Holdings, LLC | 2.06M | 1.48% | 2.06M | — | 2.06M | — | PN | Delaware | 2019-09-25 | ↗ |
| 30 | OCSL SRNE, LLC | 1.91M | 1.37% | 1.91M | — | 1.91M | — | PN | Delaware | 2019-09-25 | ↗ |
| 31 | Oaktree Specialty Lending Corporation | 1.91M | 1.37% | 1.91M | — | 1.91M | — | PN | Delaware | 2019-09-25 | ↗ |
| 32 | Ally Bridge LB Management Limited | 1.76M | 1.40% | — | 1.76M | — | — | CO | Cayman Islands | 2019-02-13 | ↗ |
| 33 | ABG Innovation-SO Limited | 1.41M | 0.80% | — | 1.41M | — | — | CO | British Virgin Islands | 2020-02-14 | ↗ |
| 34 | Oaktree Strategic Income II, Inc. | 609.8K | 0.44% | 609.8K | — | 609.8K | — | PN | Delaware | 2019-09-25 | ↗ |
| 35 | ABG II-SO Limited | 460.6K | 0.30% | — | 460.6K | — | — | CO | British Virgin Islands | 2020-02-14 | ↗ |
| 36 | Ally Bridge Group Capital Partners II, L.P. | 460.6K | 0.30% | — | 460.6K | — | — | PN | Cayman Islands | 2020-02-14 | ↗ |
| 37 | ABG Management Ltd. | — | 0.00% | — | — | — | — | CO | Cayman Islands | 2020-02-14 | ↗ |
Institutional Activity (13F)
Institutional ownership trend
Institutional history not available.
Top institutional holders
Top holders not available.
ETF Ownership
Top ETFs holding this stock
This company is not held by any ETF in our universe.
Insider Activity
Insider Activity — Latest Quarter
Ratio by transactions
0.00
Bearish
Ratio by volume
0.00
Bearish
Buys
0
Sells
1
Shares acquired
—
Shares disposed
6.31M
Cash buys
—
Cash sales
1.00
Net activity
-6,307,158
Insider buys vs sells (history)
From
To
Recent insider transactions
From
To
| Date | Person | Role | Transaction | A/D | Security | Shares | Price | Value | Owned after | D/I | Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2023-03-17 | Ji Henry | Director / Officer | X-InTheMoney | A | Common Stock | 19,500 | 0.80 | 15.7K | 20,000 | — | ↗ |
| 2022-12-21 | Ji Henry | Officer | X-InTheMoney | A | Common Stock | 300 | 5.50 | 1.7K | 500 | — | ↗ |
| 2022-12-15 | Ji Henry | Officer | A-Award | A | Common Stock | 1,500,000 | 0.00 | — | 6,265,805 | — | ↗ |
| 2022-12-02 | Ji Henry | Officer | X-InTheMoney | A | Common Stock | 200 | 5.50 | 1.1K | 200 | — | ↗ |
| 2022-09-07 | Ji Henry | Director / Officer | P-Purchase | A | Call Option (right to buy) | 759 | 12.00 | 9.1K | 759 | — | ↗ |
| 2022-09-06 | Ji Henry | Officer | P-Purchase | A | Common Stock | 55,555 | 1.96 | 108.9K | 4,676,917 | — | ↗ |
| 2022-09-02 | Ji Henry | Officer | A-Award | A | Common Stock | 2,500,000 | 0.00 | — | 4,621,362 | — | ↗ |
| 2022-08-26 | Ji Henry | Officer | P-Purchase | A | Common Stock | 33,333 | 2.11 | 70.3K | 2,121,362 | — | ↗ |
| 2022-08-25 | Ji Henry | Director / Officer | P-Purchase | A | Common Stock | 22,222 | 2.06 | 45.8K | 2,088,029 | — | ↗ |
| 2022-06-14 | Ji Henry | Officer | P-Purchase | A | Common Stock | 10,000 | 1.40 | 14.0K | 2,065,807 | — | ↗ |
| 2022-05-18 | Reilly Tammy | Director | A-Award | A | Stock Option (right to buy) | 100,000 | 0.00 | — | 100,000 | — | ↗ |
| 2022-05-18 | CZEREPAK ELIZABETH | Officer | A-Award | A | Stock Option (right to buy) | 350,000 | 0.00 | — | 350,000 | — | ↗ |
| 2021-12-31 | Janda Kim | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2021-12-27 | Janda Kim | Director | M-Exempt | D | Non-qualified stock option | 3,000 | 4.00 | 12.0K | 0 | — | ↗ |
| 2021-11-18 | CZEREPAK ELIZABETH | Director | A-Award | A | Stock Option (right to buy) | 100,000 | 6.01 | 601.0K | 100,000 | — | ↗ |
| 2021-11-15 | CZEREPAK ELIZABETH | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2021-09-29 | Ji Henry | Director / Officer | M-Exempt | A | Common Stock | 10,000 | 4.00 | 40.0K | 2,055,807 | — | ↗ |
| 2021-09-27 | Janda Kim | Director | M-Exempt | D | Stock Options | 35,000 | 1.80 | 63.0K | 0 | — | ↗ |
| 2021-09-13 | Janda Kim | Director | M-Exempt | D | Non-qualified stock option | 8,000 | 3.50 | 28.0K | 0 | — | ↗ |
| 2021-09-03 | Smith Robin L | Director | M-Exempt | A | Common Stock | 100,000 | 4.89 | 489.0K | 235,000 | — | ↗ |
| 2021-08-30 | Wu Yue Alexander | Director | A-Award | A | Stock option (right to buy) | 250,000 | 8.86 | 2.22M | 250,000 | — | ↗ |
| 2021-08-30 | Smith Robin L | Director | A-Award | A | Stock option (right to buy) | 250,000 | 8.86 | 2.22M | 250,000 | — | ↗ |
| 2021-08-30 | SHAH JAISIM | Director | A-Award | A | Stock option (right to buy) | 250,000 | 8.86 | 2.22M | 250,000 | — | ↗ |
| 2021-08-30 | Lemus David | Director | A-Award | A | Stock option (right to buy) | 250,000 | 8.86 | 2.22M | 250,000 | — | ↗ |
| 2021-08-30 | Ji Henry | Director / Officer | A-Award | A | Stock option (right to buy) | 2,500,000 | 8.86 | 22.15M | 2,500,000 | — | ↗ |
| 2021-08-30 | Janda Kim | Director | A-Award | A | Stock option (right to buy) | 250,000 | 8.86 | 2.22M | 250,000 | — | ↗ |
| 2021-08-30 | Followwill Dorman | Director | A-Award | A | Stock option (right to buy) | 250,000 | 8.86 | 2.22M | 250,000 | — | ↗ |
| 2021-04-12 | Janda Kim | Director | M-Exempt | D | Non-qualified stock option | 1,900 | 3.50 | 6.7K | 0 | — | ↗ |
| 2021-03-16 | Asghar Najjam | Officer | A-Award | A | Stock Option | 100,000 | 10.18 | 1.02M | 100,000 | — | ↗ |
| 2020-12-16 | Followwill Dorman | Director | S-Sale | D | Common Stock | 1,000 | 7.14 | 7.1K | 2,130 | — | ↗ |
| 2020-11-12 | Asghar Najjam | Officer | A-Award | A | Stock Option | 120,000 | 6.10 | 732.0K | 120,000 | — | ↗ |
| 2020-11-11 | Followwill Dorman | Director | W-Will | A | Common Stock | 1,000 | 0.00 | — | 3,130 | — | ↗ |
| 2020-10-16 | Ji Henry | Director / Officer | A-Award | A | Non-Qualified Stock Option (right to buy) | 24,935,882 | 17.30 | 431.39M | 24,935,882 | — | ↗ |
| 2020-08-18 | Asghar Najjam | Officer | — | D | Stock Options | 80,000 | 4.89 | 391.2K | 0 | — | ↗ |
| 2020-08-07 | Janda Kim | Director | A-Award | A | Stock Options | 150,000 | 14.42 | 2.16M | 150,000 | — | ↗ |
| 2020-06-15 | Wu Yue Alexander | Director | A-Award | A | Stock Options | 100,000 | 4.89 | 489.0K | 100,000 | — | ↗ |
| 2020-06-15 | Smith Robin L | Director | A-Award | A | Stock Options | 100,000 | 4.89 | 489.0K | 100,000 | — | ↗ |
| 2020-06-15 | Shao Jiong | Officer | A-Award | A | Stock Options | 120,000 | 4.89 | 586.8K | 120,000 | — | ↗ |
| 2020-06-15 | SHAH JAISIM | Director | A-Award | A | Stock Options | 100,000 | 4.89 | 489.0K | 100,000 | — | ↗ |
| 2020-06-15 | Lemus David | Director | A-Award | A | Stock Options | 100,000 | 4.89 | 489.0K | 100,000 | — | ↗ |
| 2020-06-15 | Lee Edgar | Director | A-Award | A | Stock Options | 100,000 | 4.89 | 489.0K | 100,000 | — | ↗ |
| 2020-06-15 | Ji Henry | Director / Officer | A-Award | A | Stock Options | 1,500,000 | 4.89 | 7.34M | 1,500,000 | — | ↗ |
| 2020-06-15 | Janda Kim | Director | A-Award | A | Stock Options | 100,000 | 4.89 | 489.0K | 100,000 | — | ↗ |
| 2020-06-15 | Followwill Dorman | Director | A-Award | A | Stock Options | 100,000 | 4.89 | 489.0K | 100,000 | — | ↗ |
| 2020-03-05 | Smith Robin L | Director | P-Purchase | A | Common Stock | 40,000 | 2.27 | 90.9K | 60,000 | — | ↗ |
| 2019-12-16 | Smith Robin L | Director | A-Award | A | Stock Options | 75,000 | 3.95 | 296.3K | 75,000 | — | ↗ |
| 2019-12-09 | Lee Edgar | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2019-04-19 | Wu Yue Alexander | Director | A-Award | A | Stock Options | 70,000 | 3.78 | 264.6K | 70,000 | — | ↗ |
| 2019-04-19 | Shao Jiong | Officer | A-Award | A | Stock Options | 200,000 | 3.78 | 756.0K | 200,000 | — | ↗ |
| 2019-04-19 | SHAH JAISIM | Director | A-Award | A | Stock Options | 70,000 | 3.78 | 264.6K | 70,000 | — | ↗ |
| 2019-04-19 | Lemus David | Director | A-Award | A | Stock Options | 70,000 | 3.78 | 264.6K | 70,000 | — | ↗ |
| 2019-04-19 | Ji Henry | Director / Officer | A-Award | A | Stock Options | 1,500,000 | 3.78 | 5.67M | 1,500,000 | — | ↗ |
| 2019-04-19 | Janda Kim | Director | A-Award | A | Stock Options | 70,000 | 3.78 | 264.6K | 70,000 | — | ↗ |
| 2019-04-19 | Followwill Dorman | Director | A-Award | A | Stock Options | 70,000 | 3.78 | 264.6K | 70,000 | — | ↗ |
| 2018-11-26 | ZELDIS JEROME B | Officer | A-Award | A | Stock Options | 100,000 | 3.57 | 357.0K | 100,000 | — | ↗ |
| 2018-11-26 | Wu Yue Alexander | Director | A-Award | A | Stock Options | 35,000 | 3.57 | 125.0K | 35,000 | — | ↗ |
| 2018-11-26 | Shao Jiong | Officer | A-Award | A | Stock Options | 100,000 | 3.57 | 357.0K | 100,000 | — | ↗ |
| 2018-11-26 | SHAH JAISIM | Director | A-Award | A | Stock Options | 35,000 | 3.57 | 125.0K | 35,000 | — | ↗ |
| 2018-11-26 | Lemus David | Director | A-Award | A | Stock Options | 35,000 | 3.57 | 125.0K | 35,000 | — | ↗ |
| 2018-11-26 | Janda Kim | Director | A-Award | A | Stock Options | 35,000 | 3.57 | 125.0K | 35,000 | — | ↗ |
| 2018-11-26 | Followwill Dorman | Director | A-Award | A | Stock Options | 35,000 | 3.57 | 125.0K | 35,000 | — | ↗ |
| 2018-09-13 | ABG Management Ltd | 10% Owner | S-Sale | D | Common Stock | 29,137 | 5.01 | 145.9K | 1,091,697 | — | ↗ |
| 2018-09-12 | ABG Management Ltd | 10% Owner | S-Sale | D | Common Stock | 189,754 | 5.06 | 960.1K | 1,120,834 | — | ↗ |
| 2018-07-20 | Ji Henry | Director / Officer | M-Exempt | A | Common Stock | 6,000 | 1.75 | 10.5K | 2,045,807 | — | ↗ |
| 2018-05-17 | Ji Henry | Director / Officer | A-Award | A | Stock Options | 750,000 | 7.20 | 5.40M | 750,000 | — | ↗ |
| 2018-03-19 | Shao Jiong | Officer | — | D | Stock Options | 200,000 | 7.75 | 1.55M | 0 | — | ↗ |
| 2018-02-28 | Ng George K | Officer | J-Other | A | Common Stock | 163,469 | 9.95 | 1.63M | 302,146 | — | ↗ |
| 2018-02-28 | Ji Henry | Director / Officer | J-Other | A | Common Stock | 124,298 | 9.95 | 1.24M | 260,161 | — | ↗ |
| 2018-02-28 | Ferrigno Dean | Officer | J-Other | A | Common Stock | 118 | 9.95 | 1.2K | 245 | — | ↗ |
| 2018-02-07 | ABG Management Ltd | 10% Owner | S-Sale | D | Common Stock | 150,000 | 7.19 | 1.08M | 1,328,529 | — | ↗ |
| 2018-02-06 | ABG Management Ltd | 10% Owner | S-Sale | D | Common Stock | 512,912 | 6.75 | 3.46M | 1,478,529 | — | ↗ |
| 2018-02-05 | ABG Management Ltd | 10% Owner | S-Sale | D | Common Stock | 37,483 | 8.00 | 300.0K | 3,041,759 | — | ↗ |
| 2018-01-30 | ABG Management Ltd | 10% Owner | S-Sale | D | Common Stock | 53,786 | 7.65 | 411.6K | 1,326,853 | — | ↗ |
| 2018-01-29 | ABG Management Ltd | 10% Owner | S-Sale | D | Common Stock | 39,667 | 7.61 | 301.7K | 3,203,575 | — | ↗ |
| 2018-01-25 | Ferrigno Dean | Officer | — | D | Stock Options | 100 | 5.20 | 520.00 | 0 | — | ↗ |
| 2018-01-24 | Asia Pacific MedTech (BVI) Ltd | 10% Owner | S-Sale | D | Common Stock | 577,962 | 7.52 | 4.34M | 8,617,513 | — | ↗ |
| 2018-01-23 | Asia Pacific MedTech (BVI) Ltd | 10% Owner | S-Sale | D | Common Stock | 106,326 | 7.82 | 832.0K | 9,195,475 | — | ↗ |
| 2018-01-21 | Ji Henry | Director / Officer | P-Purchase | A | Common Stock | 1,801,801 | 11,531,526.40 | 20.78T | 1,841,577 | — | ↗ |
| 2017-11-14 | Lemus David | Director | A-Award | A | Stock Options | 35,000 | 2.30 | 80.5K | 35,000 | — | ↗ |
| 2017-11-14 | Followwill Dorman | Director | A-Award | A | Stock Options | 35,000 | 2.30 | 80.5K | 35,000 | — | ↗ |
| 2017-09-26 | Lemus David | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2017-09-26 | Followwill Dorman | Director | — | D | Common Stock | 0 | 0.00 | — | 2,130 | — | ↗ |
| 2017-09-15 | Wu Yue Alexander | Director | A-Award | A | Stock Options | 35,000 | 1.80 | 63.0K | 35,000 | — | ↗ |
| 2017-09-15 | SHAH JAISIM | Director | A-Award | A | Stock Options | 35,000 | 1.80 | 63.0K | 35,000 | — | ↗ |
| 2017-09-15 | Janda Kim | Director | A-Award | A | Stock Options | 35,000 | 1.80 | 63.0K | 35,000 | — | ↗ |
| 2017-09-15 | Deming David H | Director | A-Award | A | Stock Options | 35,000 | 1.75 | 61.3K | 35,000 | — | ↗ |
| 2017-09-14 | ZELDIS JEROME B | Officer | A-Award | A | Stock Options | 150,000 | 1.80 | 270.0K | 150,000 | — | ↗ |
| 2017-09-14 | Ng George K | Officer | A-Award | A | Stock Options | 150,000 | 1.80 | 270.0K | 150,000 | — | ↗ |
| 2017-09-14 | Ji Henry | Officer | A-Award | A | Stock Options | 750,000 | 1.80 | 1.35M | 750,000 | — | ↗ |
| 2017-09-14 | Ferrigno Dean | Officer | A-Award | A | Stock Options | 25,000 | 1.80 | 45.0K | 25,000 | — | ↗ |
| 2017-09-11 | Ng George K | Officer | J-Other | A | Common Stock | 89,339 | 6.33 | 565.5K | 138,677 | — | ↗ |
| 2017-09-11 | Ji Henry | Director / Officer | J-Other | A | Common Stock | 67,932 | 6.33 | 430.0K | 135,863 | — | ↗ |
| 2017-09-11 | Ferrigno Dean | Officer | J-Other | A | Common Stock | 64 | 6.33 | 405.12 | 127 | — | ↗ |
| 2017-08-01 | Wu Yue Alexander | Director | — | D | Stock Options | 35,000 | 6.29 | 220.2K | 0 | — | ↗ |
| 2017-06-15 | SHAH JAISIM | Director | P-Purchase | A | Common Stock | 10,002 | 1.79 | 17.9K | 112,633 | — | ↗ |
| 2017-06-15 | Ji Henry | Director / Officer | P-Purchase | A | Common Stock | 9,000 | 1.84 | 16.6K | 29,001 | — | ↗ |
| 2017-05-15 | Ferrigno Dean | Officer | — | D | Common Stock | 0 | 0.00 | — | 63 | — | ↗ |
| 2017-04-19 | Ji Henry | Director / Officer | P-Purchase | A | Common Stock | 100,000 | 2.00 | 200.0K | 139,776 | — | ↗ |
| 2017-04-19 | Asia Pacific MedTech (BVI) Ltd | 10% Owner | — | D | Common Stock | 0 | 0.00 | — | 9,301,801 | — | ↗ |
| 2017-04-19 | ABG Management Ltd | 10% Owner | P-Purchase | A | Common Stock | 550,000 | 2.00 | 1.10M | 1,991,441 | — | ↗ |
| 2017-04-13 | ABG Management Ltd | 10% Owner | P-Purchase | A | Common Stock | 1,500,000 | 2.00 | 3.00M | 1,500,000 | — | ↗ |
| 2017-02-22 | Ji Henry | Director / Officer | P-Purchase | A | Common Stock | 2,000 | 5.60 | 11.2K | 39,776 | — | ↗ |
| 2017-02-10 | Ji Henry | Director / Officer | P-Purchase | A | Common Stock | 20,000 | 5.15 | 103.0K | 37,776 | — | ↗ |
| 2017-02-03 | ZELDIS JEROME B | Officer | P-Purchase | A | Common Stock | 10,000 | 5.15 | 51.5K | 10,000 | — | ↗ |
| 2017-02-03 | Wu Yue Alexander | Director | P-Purchase | A | Common Stock | 5,000 | 5.15 | 25.8K | 5,000 | — | ↗ |
| 2017-02-03 | Su Jeffrey | Officer | P-Purchase | A | Common Stock | 4,000 | 5.15 | 20.6K | 13,000 | — | ↗ |
| 2017-02-03 | SHAH JAISIM | Director | P-Purchase | A | Common Stock | 10,000 | 5.15 | 51.5K | 102,631 | — | ↗ |
| 2017-02-03 | Ng George K | Officer | S-Sale | D | Common Stock | 40,000 | 5.15 | 206.0K | 49,338 | — | ↗ |
| 2017-02-03 | Ji Henry | Director / Officer | P-Purchase | A | Common Stock | 20,000 | 5.15 | 103.0K | 37,776 | — | ↗ |
| 2017-02-03 | Janda Kim | Director | P-Purchase | A | Common Stock | 3,000 | 5.15 | 15.5K | 3,000 | — | ↗ |
| 2017-02-03 | Herde Kevin | Officer | P-Purchase | A | Common Stock | 3,000 | 5.15 | 15.5K | 7,000 | — | ↗ |
| 2017-01-05 | ABG Management Ltd | 10% Owner | J-Other | A | Common Stock | 3,243,242 | 53,502,315.00 | 173.52T | 3,243,242 | — | ↗ |
| 2016-11-11 | Ji Henry | Director / Officer | J-Other | D | Stock Options | 200,000 | 6.52 | 1.30M | 300,000 | — | ↗ |
| 2016-11-08 | Ng George K | Officer | A-Award | A | Common Stock | 89,338 | 6.33 | 565.5K | 90,226 | — | ↗ |
| 2016-11-08 | Ji Henry | Director / Officer | A-Award | A | Common Stock | 67,931 | 6.33 | 430.0K | 67,931 | — | ↗ |
| 2016-09-16 | Toledano Miranda Jayne | Officer | — | D | Stock Options | 130,000 | 6.93 | 900.9K | 0 | — | ↗ |
| 2016-08-12 | ZELDIS JEROME B | Officer | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2016-08-12 | Su Jeffrey | Officer | A-Award | A | Stock Options | 100,000 | 6.52 | 652.0K | 260,000 | — | ↗ |
| 2016-08-12 | Ng George K | Officer | A-Award | A | Stock Options | 100,000 | 6.52 | 652.0K | 260,000 | — | ↗ |
| 2016-08-12 | Ji Henry | Director / Officer | A-Award | A | Stock Options | 500,000 | 6.52 | 3.26M | 977,000 | — | ↗ |
| 2016-08-12 | Herde Kevin | Officer | A-Award | A | Stock Options | 50,000 | 6.52 | 326.0K | 130,000 | — | ↗ |
| 2016-07-11 | SHAH JAISIM | Director | A-Award | A | Stock Options | 35,000 | 6.44 | 225.4K | 305,000 | — | ↗ |
| 2016-07-11 | Marth William S | Director | A-Award | A | Stock Options | 49,000 | 6.44 | 315.6K | 182,000 | — | ↗ |
| 2016-07-11 | Janda Kim | Director | A-Award | A | Stock Options | 35,000 | 6.44 | 225.4K | 132,400 | — | ↗ |
| 2016-07-11 | EBERSOLE DOUGLAS O | Director | A-Award | A | Stock Options | 35,000 | 6.44 | 225.4K | 94,000 | — | ↗ |
| 2016-07-11 | Deming David H | Director | A-Award | A | Stock Options | 35,000 | 6.44 | 225.4K | 105,000 | — | ↗ |
| 2016-07-08 | SOON-SHIONG PATRICK | — | J-Other | D | Warrant | 500,000 | 5.80 | 2.90M | 1,224,138 | — | ↗ |
| 2016-07-07 | SOON-SHIONG PATRICK | — | S-Sale | D | Common Stock | 7,878,098 | 0.00 | 787.81 | 0 | — | ↗ |
| 2016-07-07 | ABG Management Ltd | 10% Owner | — | I | Warrants | 540,540 | 8.50 | 4.59M | 0 | — | ↗ |
| 2016-06-29 | SOON-SHIONG PATRICK | 10% Owner | S-Sale | D | Common Stock | 3,400 | 5.82 | 19.8K | 7,157,924 | — | ↗ |
| 2016-06-23 | SOON-SHIONG PATRICK | 10% Owner | S-Sale | D | Common Stock | 6,901 | 5.85 | 40.4K | 7,161,324 | — | ↗ |
| 2016-06-15 | SOON-SHIONG PATRICK | 10% Owner | S-Sale | D | Common Stock | 19,836 | 5.87 | 116.5K | 7,168,225 | — | ↗ |
| 2016-06-14 | SOON-SHIONG PATRICK | 10% Owner | S-Sale | D | Common Stock | 15,972 | 6.11 | 97.7K | 720,174 | — | ↗ |
| 2016-06-13 | SOON-SHIONG PATRICK | 10% Owner | S-Sale | D | Common Stock | 37,792 | 6.15 | 232.2K | 736,146 | — | ↗ |
| 2016-06-07 | Asia Pacific MedTech (BVI) Ltd | 10% Owner | — | D | Common Stock Warrants (Right to Buy) | 261,438 | 8.50 | 2.22M | 0 | — | ↗ |
| 2016-04-05 | Herde Kevin | Officer | — | D | Common Stock | 0 | 0.00 | — | 4,000 | — | ↗ |
| 2016-03-11 | Su Jeffrey | Officer | A-Award | A | Stock Options | 40,000 | 5.79 | 231.6K | 160,000 | — | ↗ |
| 2016-03-11 | Ng George K | Officer | A-Award | A | Stock Options | 40,000 | 5.79 | 231.6K | 160,000 | — | ↗ |
| 2016-03-11 | Ji Henry | Director / Officer | A-Award | A | Stock Options | 100,000 | 5.79 | 579.0K | 477,000 | — | ↗ |
| 2016-03-07 | SOON-SHIONG PATRICK | 10% Owner | S-Sale | D | Common Stock | 85,300 | 6.17 | 526.3K | 773,938 | — | ↗ |
| 2016-03-04 | SOON-SHIONG PATRICK | 10% Owner | S-Sale | D | Common Stock | 14,700 | 6.34 | 93.2K | 859,238 | — | ↗ |
| 2015-12-31 | SOON-SHIONG PATRICK | 10% Owner | — | D | Common Stock | 0 | 0.00 | — | 873,938 | — | ↗ |
| 2015-12-09 | SOON-SHIONG PATRICK | 10% Owner | A-Award | A | Common Stock | 39,764 | 7.93 | 315.3K | 873,938 | — | ↗ |
| 2015-12-08 | SOON-SHIONG PATRICK | 10% Owner | A-Award | A | Common Stock | 14,000 | 8.01 | 112.2K | 834,174 | — | ↗ |
| 2015-12-07 | SOON-SHIONG PATRICK | 10% Owner | A-Award | A | Common Stock | 100,000 | 7.89 | 789.1K | 820,174 | — | ↗ |
| 2015-10-19 | Su Jeffrey | Officer | — | D | Common Stock | 0 | 0.00 | — | 9,000 | — | ↗ |
| 2015-09-18 | Uy George | Officer | S-Sale | D | Common Stock | 47,500 | 12.90 | 612.8K | 201,735 | — | ↗ |
| 2015-08-26 | Ji Henry | Director / Officer | P-Purchase | A | SRNE 35 March 2016 Call Options | 497 | 0.95 | 472.15 | 497 | — | ↗ |
| 2015-08-24 | Ji Henry | Director / Officer | P-Purchase | A | Common Stock | 8,888 | 12.84 | 114.1K | 17,776 | — | ↗ |
| 2015-08-21 | Ng George K | Officer | P-Purchase | A | Common Stock | 333 | 13.55 | 4.5K | 833 | — | ↗ |
| 2015-08-21 | Ji Henry | Director / Officer | P-Purchase | A | Common Stock | 8,888 | 13.08 | 116.2K | 14,888 | — | ↗ |
| 2015-08-03 | SHAH JAISIM | Director | P-Purchase | A | Common Stock | 27,189 | 11.50 | 312.7K | 92,631 | — | ↗ |
| 2015-08-03 | Ng George K | Officer | P-Purchase | A | Common Stock | 11,453 | 11.50 | 131.7K | 14,901 | — | ↗ |
| 2015-07-28 | SOON-SHIONG PATRICK | — | G-Gift | D | Common Stock | 720,174 | 0.00 | — | 0 | — | ↗ |
| 2015-07-24 | Chan Soon-Shiong Family Foundation | 10% Owner | — | D | Common Stock | 0 | 0.00 | — | 7,188,061 | — | ↗ |
| 2015-06-04 | SHAH JAISIM | Director | A-Award | A | Stock Options | 25,000 | 13.79 | 344.8K | 270,000 | — | ↗ |
| 2015-06-04 | Marth William S | Director | A-Award | A | Stock Options | 58,000 | 13.79 | 799.8K | 133,000 | — | ↗ |
| 2015-06-04 | Janda Kim | Director | A-Award | A | Stock Options | 28,000 | 13.79 | 386.1K | 97,400 | — | ↗ |
| 2015-06-04 | EBERSOLE DOUGLAS O | Director | A-Award | A | Stock Options | 34,000 | 13.79 | 468.9K | 59,000 | — | ↗ |
| 2015-06-04 | Deming David H | Director | A-Award | A | Stock Options | 36,000 | 13.79 | 496.4K | 61,000 | — | ↗ |
| 2015-05-21 | Miao Zhenwei | Officer | G-Gift | D | Common Stock | 40,000 | 0.00 | — | 559,390 | — | ↗ |
| 2015-04-29 | Durand Mark | Officer | A-Award | A | Stock Options | 120,000 | 8.95 | 1.07M | 145,000 | — | ↗ |
| 2015-04-29 | Deming David H | Director | — | D | Stock Options | 34,000 | 8.95 | 304.3K | 0 | — | ↗ |
| 2015-03-30 | Ng George K | Officer | — | D | Stock Options | 120,000 | 8.16 | 979.2K | 0 | — | ↗ |
| 2015-03-27 | Ng George K | Officer | — | I | Common Stock | 0 | 0.00 | — | 3,448 | — | ↗ |
| 2015-02-24 | Uy George | Officer | A-Award | A | Stock Options | 80,000 | 12.78 | 1.02M | 207,000 | — | ↗ |
| 2015-02-24 | SHAH JAISIM | Director | A-Award | A | Stock Options | 80,000 | 12.78 | 1.02M | 245,000 | — | ↗ |
| 2015-02-24 | Ji Henry | Director / Officer | A-Award | A | Stock Options | 160,000 | 12.78 | 2.04M | 377,000 | — | ↗ |
| 2015-01-02 | Ji Henry | Director / Officer | G-Gift | D | Common Stock | 10,000 | 10.16 | 101.6K | 2,043,162 | — | ↗ |
| 2014-12-31 | Ji Henry | Director / Officer | G-Gift | D | Common Stock | 15,000 | 10.07 | 151.1K | 2,053,162 | — | ↗ |
| 2014-12-22 | SOON-SHIONG PATRICK | 10% Owner | — | I | Common Stock | 0 | 0.00 | — | 7,188,061 | — | ↗ |
| 2014-11-10 | Ji Henry | Director / Officer | P-Purchase | A | Common Stock | 1,000 | 4.77 | 4.8K | 12,000 | — | ↗ |
| 2014-11-07 | Ji Henry | Director / Officer | P-Purchase | A | Common Stock | 1,000 | 4.60 | 4.6K | 11,000 | — | ↗ |
| 2014-11-06 | Ji Henry | Director / Officer | P-Purchase | A | Common Stock | 1,000 | 4.50 | 4.5K | 7,000 | — | ↗ |
| 2014-10-07 | VINCENT RICHARD G | Officer | A-Award | A | Stock Options | 50,000 | 4.32 | 216.0K | 270,000 | — | ↗ |
| 2014-10-07 | Miao Zhenwei | Officer | A-Award | A | Stock Options | 50,000 | 4.32 | 216.0K | 86,000 | — | ↗ |
| 2014-10-07 | Ji Henry | Director / Officer | A-Award | A | Stock Options | 100,000 | 4.32 | 432.0K | 308,000 | — | ↗ |
| 2014-09-26 | Ji Henry | Director / Officer | G-Gift | D | Common Stock | 20,000 | 0.00 | — | 2,068,162 | — | ↗ |
| 2014-09-18 | Uy George | Officer | A-Award | A | Stock Options | 80,000 | 4.78 | 382.4K | 127,000 | — | ↗ |
| 2014-09-18 | SHAH JAISIM | Director | A-Award | A | Stock Options | 25,000 | 4.78 | 119.5K | 165,000 | — | ↗ |
| 2014-09-18 | Marth William S | Director | A-Award | A | Stock Options | 25,000 | 4.78 | 119.5K | 75,000 | — | ↗ |
| 2014-09-18 | Janda Kim | Director | A-Award | A | Stock Options | 12,500 | 4.78 | 59.8K | 69,400 | — | ↗ |
| 2014-09-18 | EBERSOLE DOUGLAS O | Director | A-Award | A | Stock Options | 12,000 | 4.78 | 57.4K | 25,000 | — | ↗ |
| 2014-09-18 | Durand Mark | Director | A-Award | A | Stock Options | 12,000 | 4.78 | 57.4K | 25,000 | — | ↗ |
| 2014-08-06 | EBERSOLE DOUGLAS O | Director | — | D | Stock Options | 13,000 | 5.34 | 69.4K | 0 | — | ↗ |
| 2014-06-27 | Royal Mike | Officer | — | D | Stock Options | 15,000 | 6.63 | 99.5K | 0 | — | ↗ |
| 2014-06-05 | Ji Henry | Director / Officer | J-Other | D | Common Stock | 250,000 | 0.00 | — | 2,088,162 | — | ↗ |
| 2014-03-07 | Durand Mark | Director | — | D | Stock Options | 13,000 | 13.53 | 175.9K | 0 | — | ↗ |
| 2014-01-30 | LEVITT DANIEL J | Director | — | D | Stock Options | 13,000 | 9.90 | 128.7K | 0 | — | ↗ |
| 2014-01-23 | Salka Michael Scott | Director | A-Award | A | Stock Options | 10,000 | 9.82 | 98.2K | 38,000 | — | ↗ |
| 2014-01-23 | Marth William S | Director | A-Award | A | Stock Options | 37,000 | 9.82 | 363.3K | 50,000 | — | ↗ |
| 2014-01-23 | Janda Kim | Director | A-Award | A | Stock Options | 10,000 | 9.82 | 98.2K | 56,900 | — | ↗ |
| 2014-01-23 | Gallagher Cam | Director | A-Award | A | Stock Options | 10,000 | 9.82 | 98.2K | 35,000 | — | ↗ |
| 2014-01-07 | Marth William S | Director | — | D | Stock Options | 13,000 | 8.20 | 106.6K | 0 | — | ↗ |
| 2014-01-06 | Singh Amar | Director / Officer | — | D | Stock Options | 80,000 | 8.20 | 656.0K | 0 | — | ↗ |
| 2013-12-19 | Miao Zhenwei | Officer | — | D | Stock Options | 36,000 | 13.53 | 487.1K | 0 | — | ↗ |
| 2013-12-05 | Ji Henry | Director / Officer | P-Purchase | A | Common Stock | 500 | 8.95 | 4.5K | 1,728,162 | — | ↗ |
| 2013-12-04 | Ji Henry | Director / Officer | P-Purchase | A | Common Stock | 500 | 8.53 | 4.3K | 1,726,662 | — | ↗ |
| 2013-11-26 | Opko Health, Inc. | 10% Owner | S-Sale | D | Common Stock | 8,714 | 8.54 | 74.4K | 2,153,045 | — | ↗ |
| 2013-11-25 | SHAH JAISIM | Director | P-Purchase | A | Common Stock | 1,000 | 8.65 | 8.7K | 65,442 | — | ↗ |
Executive team
Top executives
EBIT / Employee
-5.8K
Shares Outstanding
551.28M
Executive compensation
Executive compensation (annual)
| # | Year | Executive | Salary | Bonus | Stock award | Option award | Incentive | Other | Total | % Stock- based |
Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 2021 | Henry Ji, Ph.D. Chairman of the Board, Chief Executive Officer and President | 1.64M | — | — | 18.09M | — | 52.8K | 19.78M | 91.44% | ↗ |
| 2 | 2021 | Najjam Asghar Former Senior Vice President and Chief Financial Officer | 450.0K | — | 580.0K | 832.7K | — | 37.3K | 1.90M | 74.35% | ↗ |
| 3 | 2020 | Henry Ji, Ph.D. Chairman of the Board, Chief Executive Officer and President | 839.3K | 560.0K | — | 156.09M | — | 51.4K | 157.54M | 99.08% | ↗ |
| 4 | 2020 | Najjam Asghar Senior Vice President and Chief Financial Officer | 318.4K | 160.0K | — | 1.52M | — | 33.3K | 2.03M | 74.82% | ↗ |
| 5 | 2020 | Najjam Asghar Former Senior Vice President and Chief Financial Officer | 318.4K | 160.0K | — | 1.52M | — | 33.3K | 2.03M | 74.82% | ↗ |
| 6 | 2020 | Jiong Shao Former Executive Vice President and Former Chief Financial Officer | 336.3K | — | — | 462.0K | — | 23.3K | 821.6K | 56.23% | ↗ |
| 7 | 2019 | Henry Ji, Ph.D. Chairman of the Board, Chief Executive Officer and President | 781.4K | — | — | 7.32M | — | 12.8K | 8.11M | 90.21% | ↗ |
| 8 | 2019 | Jiong Shao Former Executive Vice President and Former Chief Financial Officer | 450.0K | — | — | 776.2K | — | 6.2K | 1.23M | 62.98% | ↗ |
| 9 | 2019 | Jiong Shao Former Executive Vice President and Chief Financial Officer | 450.0K | — | — | 776.2K | — | 6.2K | 1.23M | 62.98% | ↗ |
| 10 | 2018 | Henry Ji, Ph.D. Chairman of the Board, Chief Executive Officer and President | 670.0K | — | — | 3.83M | — | — | 4.50M | 85.12% | ↗ |
| 11 | 2018 | Jiong Shao Executive Vice President and Chief Financial Officer | 356.3K | — | — | 2.99M | — | — | 3.35M | 89.36% | ↗ |
| 12 | 2018 | Jiong Shao Former Executive Vice President and Former Chief Financial Officer | 356.3K | — | — | 2.99M | — | — | 3.35M | 89.36% | ↗ |
| 13 | 2018 | Jiong Shao Former Executive Vice President and Chief Financial Officer | 356.3K | — | — | 2.99M | — | — | 3.35M | 89.36% | ↗ |
| 14 | 2018 | George K. Ng Former EVP and Chief Administrative Officer and Chief Legal Officer | 468.0K | — | — | 810.0K | — | — | 1.28M | 63.38% | ↗ |
| 15 | 2018 | Jerome Zeldis, M.D., Ph.D. Chief Medical Officer and President of Clinical Development | 305.0K | — | — | 253.0K | — | — | 558.0K | 45.34% | ↗ |
| 16 | 2018 | Dean Ferrigno Former Chief Accounting Officer | 66.4K | — | — | — | — | — | 66.4K | 0.00% | ↗ |
| 17 | 2017 | Henry Ji, Ph.D. Chairman of the Board, Chief Executive Officer and President | 600.0K | — | — | 945.0K | — | — | 1.55M | 61.17% | ↗ |
| 18 | 2017 | George K. Ng Former EVP and Chief Administrative Officer and Chief Legal Officer | 450.0K | 118.1K | — | 189.0K | — | 48.5K | 805.7K | 23.46% | ↗ |
| 19 | 2017 | George K. Ng EVP and Chief Administrative Officer and Chief Legal Officer | 450.0K | — | — | 189.0K | — | 48.5K | 687.5K | 27.49% | ↗ |
| 20 | 2017 | Jerome Zeldis, M.D., Ph.D. Chief Medical Officer and President of Clinical Development | 275.0K | 82.5K | — | 189.0K | — | — | 546.5K | 34.58% | ↗ |
| 21 | 2017 | Dean Ferrigno Former Chief Accounting Officer | 225.0K | — | — | 133.9K | — | — | 358.9K | 37.31% | ↗ |
| 22 | 2017 | Kevin Herde Former EVP and Chief Financial Officer | 143.9K | 100.0K | — | — | — | 65.0K | 308.9K | 0.00% | ↗ |
| 23 | 2016 | Henry Ji, Ph.D. Chief Executive Officer and President | 600.0K | 200.0K | — | 1.67M | — | — | 2.47M | 67.60% | ↗ |
| 24 | 2016 | Henry Ji, Ph.D. Chairman of the Board, Chief Executive Officer and President | 600.0K | 200.0K | — | 1.67M | — | — | 2.47M | 67.60% | ↗ |
| 25 | 2016 | George K. Ng Former EVP and Chief Administrative Officer and Chief Legal Officer | 450.0K | — | — | 581.8K | — | 101.5K | 1.13M | 51.34% | ↗ |
| 26 | 2016 | George K. Ng EVP and Chief Administrative Officer and Chief Legal Officer | 450.0K | — | — | 581.8K | — | 101.5K | 1.13M | 51.34% | ↗ |
| 27 | 2016 | Jeffrey Su, Ph.D. EVP and Chief Operating Officer | 414.0K | 100.0K | — | 581.8K | — | — | 1.10M | 53.09% | ↗ |
| 28 | 2016 | Jerome Zeldis, M.D., Ph.D. Chief Medical Officer and President of Clinical Development | 103.1K | 41.3K | — | 858.0K | — | — | 1.00M | 85.60% | ↗ |
| 29 | 2016 | Kevin Herde Former EVP and Chief Financial Officer | 234.0K | — | — | 557.7K | — | — | 791.7K | 70.45% | ↗ |
| 30 | 2016 | Douglas Langston Former Vice President, Finance | 200.3K | — | — | 38.6K | — | 75.1K | 314.0K | 12.29% | ↗ |
| 31 | 2015 | Henry Ji, Ph.D. Chairman of the Board, Chief Executive Officer and President | 500.0K | 575.0K | — | 1.97M | — | — | 3.04M | 64.68% | ↗ |
| 32 | 2015 | Henry Ji, Ph.D. Chief Executive Officer and President | 500.0K | 575.0K | — | 1.97M | — | — | 3.04M | 64.68% | ↗ |
| 33 | 2015 | David Miao Former SVP, Head of ADC Development | 250.0K | 50.0K | — | — | — | 927.4K | 1.23M | 0.00% | ↗ |
| 34 | 2015 | Mark Durand Former Executive Vice President and Chief Financial Officer | 67.0K | — | 706.8K | — | — | 191.0K | 964.8K | 73.26% | ↗ |
| 35 | 2015 | Jeffrey Su, Ph.D. EVP and Chief Operating Officer | 83.3K | 81.7K | — | 702.1K | — | — | 867.1K | 80.97% | ↗ |
| 36 | 2015 | George K. Ng EVP and Chief Administrative Officer and Chief Legal Officer | 306.9K | 468.7K | — | 19.6K | — | — | 795.2K | 2.46% | ↗ |
| 37 | 2015 | Jeffrey Su EVP and Chief Operating Officer | 83.3K | — | 702.1K | — | — | 7.3K | 792.7K | 88.57% | ↗ |
| 38 | 2015 | George H. Ng EVP and Chief Administrative Officer and Chief Legal Officer | 306.9K | 348.9K | 19.6K | — | — | 29.4K | 704.8K | 2.78% | ↗ |
| 39 | 2015 | Mike Royal Former EVP, Clinical and Regulatory Affairs | 400.0K | 120.8K | — | — | — | 36.3K | 557.0K | 0.00% | ↗ |
| 40 | 2015 | Richard Vincent Former Executive Vice President and Chief Financial Officer | 51.2K | — | — | — | — | 367.2K | 418.4K | 0.00% | ↗ |
| 41 | 2015 | Douglas Langston Former Vice President, Finance | 250.0K | 123.6K | — | 777.00 | — | — | 374.4K | 0.21% | ↗ |
| 42 | 2015 | Douglas Langston Vice President, Finance | 250.0K | 73.6K | 777.00 | — | — | 27.3K | 351.6K | 0.22% | ↗ |
| 43 | 2014 | Mike Royal EVP, Clinical and Regulatory Affairs | 287.5K | 50.0K | 787.9K | — | — | 32.1K | 1.16M | 68.07% | ↗ |
| 44 | 2014 | Mike Royal Former EVP, Clinical and Regulatory Affairs | 287.5K | 50.0K | 787.9K | — | — | 32.1K | 1.16M | 68.07% | ↗ |
| 45 | 2014 | Henry Ji, Ph.D. Chief Executive Officer and President | 425.0K | 157.5K | 286.0K | — | — | 27.0K | 895.5K | 31.94% | ↗ |
| 46 | 2014 | Henry Ji, Ph.D. Chief Executive Officer and President | 425.0K | 157.5K | — | 286.0K | — | — | 868.5K | 32.93% | ↗ |
| 47 | 2014 | David Miao Former SVP, Head of ADC Development | 250.0K | — | 143.0K | — | — | 267.7K | 660.7K | 21.65% | ↗ |
| 48 | 2014 | David Miao Chief Technical Officer | 250.0K | 240.0K | 143.0K | — | — | 27.7K | 660.7K | 21.65% | ↗ |
| 49 | 2014 | George K. Ng EVP and Chief Administrative Officer and Chief Legal Officer | — | — | — | 648.0K | — | — | 648.0K | 100.00% | ↗ |
| 50 | 2014 | George H. Ng EVP and Chief Administrative Officer and Chief Legal Officer | — | — | 648.0K | — | — | — | 648.0K | 100.00% | ↗ |
| 51 | 2014 | George Uy EVP and Chief Commercial Officer | 304.7K | 36.5K | 260.8K | — | — | 35.5K | 637.5K | 40.91% | ↗ |
| 52 | 2014 | Richard Vincent Former Executive Vice President and Chief Financial Officer | 365.2K | 70.0K | 143.0K | — | — | 23.9K | 602.1K | 23.75% | ↗ |
| 53 | 2014 | Richard Vincent Former Chief Financial Officer | 365.2K | 70.0K | 143.0K | — | — | 23.9K | 602.1K | 23.75% | ↗ |
| 54 | 2014 | Douglas Langston Vice President, Finance | 179.2K | — | 140.2K | — | — | 26.5K | 345.8K | 40.53% | ↗ |
| 55 | 2014 | Douglas Langston Former Vice President, Finance | 179.2K | — | — | 140.2K | — | — | 319.3K | 43.89% | ↗ |
| 56 | 2013 | Henry Ji, Ph.D. Chief Executive Officer and President | 291.4K | — | 576.7K | — | — | 28.7K | 896.8K | 64.31% | ↗ |
| 57 | 2013 | Henry Ji, Ph.D. Chief Executive Officer and President | 291.4K | — | 576.7K | — | — | 28.7K | 896.8K | 64.31% | ↗ |
| 58 | 2013 | Richard Vincent Former Executive Vice President and Chief Financial Officer | 296.0K | — | 571.0K | — | — | 25.6K | 893.6K | 63.90% | ↗ |
| 59 | 2013 | Richard Vincent Former Chief Financial Officer | 296.0K | — | 571.0K | — | — | 25.6K | 893.6K | 63.90% | ↗ |
| 60 | 2013 | Richard Vincent Chief Financial Officer | 296.0K | — | 571.0K | — | — | 25.6K | 893.6K | 63.90% | ↗ |
| 61 | 2013 | David Miao Chief Technical Officer | 8.7K | 400.0K | — | — | — | — | 408.7K | 0.00% | ↗ |
| 62 | 2013 | David Miao Former SVP, Head of ADC Development | 8.7K | — | — | — | — | 400.0K | 408.7K | 0.00% | ↗ |
| 63 | 2013 | David Miao Chief Technical Officer | 8.7K | 400.0K | — | — | — | — | 408.7K | 0.00% | ↗ |
| 64 | 2013 | Chief Scientific Officer | 84.8K | — | 205.6K | — | — | 3.5K | 293.9K | 69.95% | ↗ |
| 65 | 2013 | Mike Royal EVP, Clinical and Regulatory Affairs | 84.8K | — | 205.6K | — | — | 3.5K | 293.9K | 69.95% | ↗ |
| 66 | 2013 | George Uy EVP and Chief Commercial Officer | 84.8K | — | 205.6K | — | — | 3.5K | 293.9K | 69.95% | ↗ |
| 67 | 2013 | Vuong Trieu | 84.8K | — | 205.6K | — | — | 3.5K | 293.9K | 69.95% | ↗ |
| 68 | 2013 | Mike Royal Former EVP, Clinical and Regulatory Affairs | 84.8K | — | 205.6K | — | — | 3.5K | 293.9K | 69.95% | ↗ |
| 69 | 2012 | Richard Vincent Chief Financial Officer | 183.5K | — | 312.0K | — | — | 4.7K | 500.2K | 62.37% | ↗ |
| 70 | 2012 | Henry Ji, Ph.D. Chief Executive Officer and President | 255.2K | — | 32.5K | — | — | 19.3K | 307.0K | 10.59% | ↗ |
| 71 | 2011 | Henry Ji, Ph.D. Chief Executive Officer and President | 240.0K | — | — | — | — | 22.4K | 262.4K | 0.00% | ↗ |
| 72 | 2011 | Richard Vincent Chief Financial Officer | 117.5K | — | 63.5K | — | — | — | 181.0K | 35.08% | ↗ |
| 73 | 2010 | Richard Vincent Chief Financial Officer | 65.5K | — | 6.4K | — | — | — | 71.9K | 8.90% | ↗ |
CEO compensation breakdown
Proxy statements
Proxy statements (DEF 14A)
Recent SEC filings
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Henry H. Ji | Chairman, President & Chief Executive Officer | 2M | — |
| Scott Schaus | Chief Technology Officer | — | — |
ESG Rating
ESG Score History BIOTECHNOLOGY
Benchmark vs Sector
Senate Trading Activity
No Senate trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for SRNE
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
